Davita Inc vs Uranium Energy Corp — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Uranium Energy Corp trades at $9.25 (market cap $4.69B). The key difference: Davita Inc is far larger — about 2.4× Uranium Energy Corp's market cap, and Davita Inc is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Uranium Energy Corp for 37 Days on average.
| DVA | UEC | |
|---|---|---|
Market Cap | $11.28B | $4.69B |
Volume | 650,294 | 8,957,476 |
Sector | Health | Energy |
52-Week High | $240.96 | $20.14 |
52-Week Low | $103.87 | $9.04 |
Typical Hold Time | 113 Days | 37 Days |
Enterprise Value | $24.00B | $4.20B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Uranium Energy (UEC) trades at $9.47, down 6.33% today, amid bearish technical signals despite strong analyst support. The company reported fiscal 2026 revenue of $37M with a net loss of $137M, reflecting operational expansion but negative profitability. Recent news highlights UEC's transition to a multi-mine producer with improved production scale and a $93.13 realized uranium price, though earnings quality concerns persist due to inventory-driven revenue.
UEC presents a high-risk, high-reward opportunity with Wall Street optimism (87.5% buy ratings, $16.06 consensus target) contrasting weak fundamentals. Key risks include sustained losses, unproven production sustainability, and uranium price volatility. The stock's upside depends on successful execution of U.S. uranium production ramp-up amid growing nuclear demand.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →